Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

Determine the effect of treatment with INCB019602 administered as an add-on to stable dose metformin therapy in type 2 diabetic subjects on safety and glycemic control.

Key facts

Study ID

NCT00698789

Run by

Incyte Corporation

People needed

48

Starts

2008-05-01

Expected to finish

2009-06-01

Last updated by the study team

2012-10-30

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Established diagnosis of T2D
• Currently taking metformin monotherapy at a stable dose level
• FPG between 150 and 270 mg/dL

You may not qualify if…

• History or clinical manifestations of renal impairment
• Hyperglycemia > 270 mg/dL
• Receiving thiazolidenediones, Exenatide or sulfonylureas within 90 days prior to screening
• Prior use of Acipimox which is known under the name Olbetam within 90 days prior to screening.
• Diagnosed major depression within the last 2 years requiring hospitalization
• History of chronic insulin therapy for glycemic control

Where it is running

• Study site — Phoenix, Arizona, United States
• Study site — Tucson, Arizona, United States
• Study site — Chula Vista, California, United States
• Study site — Los Angeles, California, United States
• Study site — Mission Viejo, California, United States
• Study site — Orange, California, United States
• Study site — Paramount, California, United States
• Study site — San Diego, California, United States
• Study site — Santa Ana, California, United States
• Study site — Tustin, California, United States
• Study site — Colorado Springs, Colorado, United States
• Study site — St. Petersburg, Florida, United States
• Study site — Shawnee Mission, Kansas, United States
• Study site — Shreveport, Louisiana, United States
• Study site — Dearborn, Michigan, United States
• Study site — St Louis, Missouri, United States
• Study site — Omaha, Nebraska, United States
• Study site — Elizabeth, New Jersey, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Oklahoma City, Oklahoma, United States
• Study site — East Providence, Rhode Island, United States
• Study site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.